EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare, skin care and wound care products, has announced preliminary net revenue of $2.4 million for the second quarter of 2024 and $5.0 million for the first half of 2024, primarily derived from the company’s eyecare products. Net revenue from the company’s eyecare products increased by 9 percent for both the second quarter and the first half of 2024 compared with the corresponding periods in 2023, the company noted. NovaBay also said it expects 2024 net revenue from the company’s eyecare products to be approximately $10 million. Read More